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a  b  s  t  r  a  c  t
A  vaccine  for  malaria  is  urgently  required.  The  RTS,S  vaccine  represents  major  progress,  but is only
partially  effective.  Development  of the  next generation  of highly  effective  vaccines  requires elucidation
of  the  protective  immune  response.  Immunity  to  malaria  is  known  to  be complex,  and  pattern-based
approaches  such  as global  gene  expression  proﬁling  are  ideal  for understanding  response  to vaccination
and  protection  against  disease.  The  availability  of  experimental  sporozoite  challenge  in humans  to test
candidate  malaria  vaccines  offers a  precious  opportunity  unavailable  for  other current  targets  of vaccine
research  such  as  HIV,  tuberculosis  and  Ebola.  However,  a limited  number  of  transcriptional  proﬁling
studies  in  the  context  of  malaria  vaccine  research  have  been  published  to  date.  This  review  outlines  the
background,  existing  studies,  limits  and opportunities  for gene  expression  studies  to  accelerate  malaria
vaccine  research.
©  2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Malaria remains one of the world’s biggest killers with an
estimated 584,000 deaths attributable to Plasmodium falciparum
infection in 2013 [1]. The spectres of emerging resistance of the
parasite to artemisinin drugs [2], and increasing resistance of
mosquitoes to insecticides [3] mean a vaccine is urgently required.
There has been considerable progress towards a vaccine, most
notably the RTS,S vaccine, but this vaccine is only partially effec-
tive [4]. In order to design the next generation of vaccines it is
imperative to maximise our understanding of the mechanisms
of protective immune responses evoked by existing candidate
vaccines. Malaria is unusual in having the advantage of human
sporozoite challenge for rapid assessment of candidate vaccines.
Exploration of mechanisms of immune protection is therefore valu-
able for vaccine research beyond malaria.
Naturally acquired immunity to malaria requires repeated expo-
sure and is non-sterile, short-lived, and species-, strain- and
variant-speciﬁc [5,6]. Protective immune responses against malaria
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may  be humoral or cellular, and can be directed at the pre-
erythrocytic parasite, the blood stage merozoite, or to malarial
antigens on the surface of infected erythrocytes. The relative
importance of different immune responses to malaria measured
in exposed populations is unknown. Furthermore, many ﬁndings
have not been reproduced in separate populations. It is likely that
high level protection against malaria in humans depends on the
summed effect of multiple low level immune responses to several
antigens, with a different “protective signature” for each person
depending on their genetic background [7].
Parasite diversity represents a major obstacle to malaria vac-
cine development [8]. For example, around 60 different var genes
encode P. falciparum erythrocyte membrane protein 1 (PfEMP1)
[9], and this parasite diversity contributes to the slow speed
of acquisition of natural immunity [10]. Assessment of potential
markers of immunity is hindered by the fact that speciﬁc responses
may  be short-lived and ﬂuctuate with malaria season and degree of
parasitaemia [11]. Although used extensively as surrogate markers
of immunity to malaria for both vaccine studies and naturally
exposed populations, neither antibody levels nor IFN- secre-
tion, measured by ex vivo and cultured ELISPOT (enzyme-linked
immunospot assay) correlate with protection consistently between
studies. As malaria is an intracellular parasite, it is likely that a
protective vaccine would activate the cellular arm of the immune
response and be effective against the pre-erythrocytic liver stage
http://dx.doi.org/10.1016/j.vaccine.2015.07.107
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of the life cycle. It is highly possible that a combination of several
pathways is required. P. falciparum causes the majority of deaths,
and this parasite is the focus of most research for a malaria vaccine.
However, Plasmodium vivax represents a serious threat to global
health.
Global pattern recognition approaches have great potential to
unravel the mechanisms of protection against malaria by candi-
date malaria vaccines. Such approaches supplement traditional
techniques of antibody measurement and quantiﬁcation of speciﬁc
pre-determined cellular responses. This review focuses on the use
of transcriptomics in malaria vaccine research.
2. Malaria vaccines
The feasibility of a malaria vaccine is supported by two  main
ﬁndings. Firstly, people in endemic areas accumulate considerable
protection against clinical disease [12]. Secondly, 90% of volunteers
receiving a repeated series of irradiated sporozoites via infected
mosquitoes demonstrate sterile protection to over several months
[13]. This irradiated sporozoite approach was originally considered
only a research tool because of practical issues scaling for tropical
settings. However there is now a focussed programme evaluating
mass production which has reported success in malaria-naïve sub-
jects using a stored preparation of irradiated sporozoites delivered
by the intravenous route [14].
Candidate vaccine regimens currently undergoing clinical tri-
als can be viewed online in the WHO’s “rainbow tables” [15] and
in recent reviews [16,17]. Malaria vaccine strategies have typ-
ically targeted one or a few antigens from one of the distinct
life-cycle stages. This is in contrast to naturally acquired immunity
which is likely to involve broad spectrum immunity to a range of
antigens across life-cycle stages [6]. Analysis of the P. falciparum
proteome revealed that the expression of key malarial antigens
is often not as stage-speciﬁc as was traditionally thought [18].
Nevertheless, certain antigens predominate at each stage. Increas-
ingly, research groups are combining antigens from more than one
lifecycle stage to develop “multi-stage” vaccines, although main-
taining potency in a combined antigen approach can be problematic
[19,20].
Pre-erythrocytic vaccines act during the parasite’s brief journey
from the skin to the liver, or target infected hepatocytes. The most
advanced candidate malaria vaccine is the CSP-based subunit vac-
cine RTS,S (GlaxoSmithKline Biologicals, Rixensart, Belgium/Walter
Reed Army Institute of Research). This is a protein-in-adjuvant vac-
cine, which targets the pre-erythrocytic stage circumsporozoite
protein. A large number of clinical studies have featured in its
development (reviewed in Ref. [21]), including a study comparing
the adjuvants AS01B and AS02A with saline in 102 malaria-naïve
healthy adults in the USA [22]. This study is a rich resource for
exploring why some subjects were protected by the vaccine and
some were not. A Phase III trial showed efﬁcacy against ﬁrst episode
of clinical malaria of 46% in children in the ﬁrst 18 months [4]
but efﬁcacy in infants was less at 27%. Efforts continue to improve
this efﬁcacy, building on previous attempts to combine RTS,S with
other antigens [23] or combine the RTS,S vaccine in a prime-boost
strategy [24,25].
Other pre-erythrocytic stage approaches include prime-boost
strategies to deliver the same antigen in different carriers, often
using viral vectors, to optimise the innate immune milieu for
antigen presentation [26]. Examples include using simian adeno-
virus ChAd63 as a viral vector with modiﬁed vaccinia virus Ankara
(MVA) encoding TRAP (thrombospondin-related adhesion protein)
[27,28], and a DNA prime, human serotype 5 adenovirus boost reg-
imen encoding both CSP and apical membrane antigen-1 (AMA-1)
[29].
Blood stage vaccines are “anti-disease” vaccines that aim to
prevent invasion of blood cells after the liver stage, or prevent
the complications of disease, by targeting merozoite invasion of
erythrocytes, parasitised erythrocytes or prevent sequestration.
Finally, transmission-blocking vaccines seek to generate immunity
against sexual stages of the parasite [30,31]. However, current pub-
lished studies available for transcriptome studies in malaria vaccine
research are for pre-erythrocytic vaccines, which are the focus of
this review.
3. Controlled human malaria infection studies
The availability of a human experimental sporozoite chal-
lenge model for assessing protective efﬁcacy of candidate vaccines
provides an excellent opportunity to study immune responses fol-
lowing vaccination in relation to efﬁcacy (reviewed in Refs. [32,33].
Vaccinated volunteers and control participants undergo controlled
human malaria infection (CHMI) challenge with P. falciparum at the
peak vaccine immune response by one of three methods: via the
bites of infectious mosquitoes [34,35], by needle-based adminis-
tration of cryopreserved sporozoites [36] or by infected red blood
cells [37,38]. For the exposure to mosquito bites CHMI method,
laboratory-reared Anopheles stephensi mosquitoes are infected with
drug-sensitive 3D7 or NF54 strain P. falciparum parasites by game-
tocyte culture and feeding [39]. Each participant is then exposed
to the bites of ﬁve infected mosquitoes. Subjects are monitored
intensively by blood ﬁlm and quantitative PCR analysis, and treated
immediately on reaching a challenge endpoint. Vaccinated subjects
can be completely protected against challenge (“sterile protec-
tion”), show a delay to parasitaemia of at least 48 h compared to
unvaccinated control subjects consistent with partial protection
[40], or show no protection.
4. Immunity to malaria vaccines
There are many published studies exploring immune corre-
lates of protection by the RTS,S vaccine. However, a large gap
remains in our understanding of mechanisms of protection by pre-
erythrocytic candidate vaccines. Anti-CSP antibodies are associated
with protection, with a mathematical model predicting that a titre
of 51 units/ml would prevent 50% of infections and clinical malaria
episodes in children [41]. However, other immune mechanisms
contributing to protection are not well characterised. Natural expo-
sure does not induce strong levels of anti-CSP antibodies, and there
is no evidence of boosting of RTS,S-induced anti-CSP responses by
natural exposure [42]. A clinical study in malaria-naïve subjects
comparing the two adjuvants AS02A and AS01B with saline [43]
demonstrated signiﬁcantly higher anti-CSP titres induced by both
AS02A and AS01B adjuvants compared to saline, supporting the
adjuvant being a crucial factor for antibody induction. A number of
studies have explored T cell responses to RTS,S [43–49] with rela-
tionships described, including an independent association between
CSP-speciﬁc TNF+ CD4+ T cells and protection in Kenyan children
[44]. Models support a contribution to protection by CD4+ T cells
in malaria-naïve volunteers undergoing sporozoite challenge after
RTS,S [50]. There is evidence from murine studies that anti-CSP
speciﬁc CD8 T cells can protect against malaria [51] but RTS,S does
not appear to be a potent induced of CD8 T cells. A greater under-
standing of the role of regulatory immune responses to candidate
malaria vaccines is also required to optimise design [59]. Further
work exploring the interaction in endemic regions between RTS,S
vaccination, pre-existing immunity and post-vaccination malaria
exposure is of importance. Interestingly a recent study of the
breadth of humoral responses using protein arrays [52] was  con-
sistent with RTS,S vaccination leading to lower exposure to liver
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and blood stage parasites. This contrasted with the hypothesis that
a partially effective RTS,S would lead to lower numbers of parasites
emerging from the liver favouring a prolonged low level blood stage
which in turn would facilitate naturally acquired blood stage immu-
nity to supplement the anti-CSP antibodies. The protein array data
supports an all-or-nothing hypothesis whereby malaria is either
prevented by blocking sporozoite invasion of hepatocytes, or not.
The prime-boost approach is a good platform for induction
of CD8 T cells [53,54]. A correlation in humans between IFN--
producing CD8+ T cells and protection against sporozoite challenge
was reported for the ChAd63-MVA regimen encoding ME  TRAP [27].
Elsewhere, analysis for immune correlates of protection in the four
subjects protected by the DNA-Ad5 regimen encoding CSP AMA-1
[29] showed higher effector to central memory CD8+ T cell ratios
to AMA1 in three subjects and to CSP in one subject [55].
Transcriptional proﬁling of the vaccine response and
integration with outcome data from clinical challenge
studies
There are very limited studies available of transcriptional pro-
ﬁling in the context of malaria vaccine development. In a murine
Plasmodium yoelii model, Tse et al. at Johns Hopkins University
Bloomberg School of Public Health characterised the gene expres-
sion of CSP-speciﬁc memory CD8+ T cells residing in the liver and
spleen after immunisation with irradiated sporozoites [56]. Differ-
ences in the expression of a number of genes involved in effector
function, the cell cycle, cell trafﬁcking, transcription and intracellu-
lar signalling were reported. There was evidence of persistent T-cell
activation in the liver including upregulation of CD69 expression
and genes from effector pathways, consistent with prolonged Plas-
modium antigen presentation. However, the transcriptional proﬁle
in the liver did not resemble the “memory signature” seen by
repeated Listeria exposure [57], or the T-cell exhaustion proﬁle
reported in chronic viral infection [58] in other murine studies. This
study demonstrates the unique environment of the liver for the
development of immunity to malaria, and is a reminder that study-
ing transcription signature in only the peripheral blood is likely
to miss some details of protective responses. The ﬁnding that the
molecular signature for Plasmodium-exposed CD8+ T cells in the
liver is distinct from those reported for other pathogens is impor-
tant for understanding the mechanism of responses to malaria.
Vahey and colleagues at Walter Reed Army Institute of Research
performed transcriptional proﬁling of 39 malaria-naïve human
subjects in a study of RTS,S [59]. These subjects received either
the AS01B or the AS02A adjuvant [22]. In a subsequent sporozoite
challenge, 13/39 had sterile protection against malaria, 11/39 had
a delay to parasitaemia and 15/39 had no protection. Gene expres-
sion studies were performed using peripheral blood mononuclear
cells (PBMC) from subjects isolated at several points in the trial.
Transitory changes in genes relating to a number of inﬂamma-
tory processes including apoptosis and protein kinase cascade were
reported 24 h after the ﬁnal vaccine. These could relate to the adju-
vant, the Hepatitis B antigen in the vaccine or the CSP epitope.
Five days after sporozoite challenge, principal component analy-
sis (PCA) showed clustering of PBMC into distinct groups of those
challenged but not vaccinated, those challenged and vaccinated,
and the same subjects before vaccination or challenge. This demon-
strated that subjects vaccinated with RTS,S respond differently to
challenge compared to unvaccinated subjects, as early as ﬁve days
post challenge, although the genes and pathways associated with
these clusters were not reported. Classiﬁcation and prediction anal-
ysis at this timepoint ﬁve days after challenge predicted with 100%
accuracy whether a subject went on to be completely, partially or
not protected against malaria, using a classiﬁer set of 393 genes
including genes associated with the cell cycle and regulation of apo-
ptosis. This classiﬁer set was  only predictive when measured ﬁve
days after challenge, and was  unable to classify by outcome prior
to challenge (two weeks after ﬁnal vaccination). However gene
set enrichment analysis (GSEA) at this pre-challenge timepoint
found differential expression of genes in the proteasome degrada-
tion pathway in protected subjects compared to the non-protected
subjects, in particular for genes in the “immunoproteasome” sub-
group involved in processing peptides for Major Histocompatibility
Complex (MHC) Class 1 pathways.
This work is important because RTS,S is not thought to be
a potent inducer of CD8+ T cell responses, yet this study pro-
vides evidence of the pivotal role of CD8+/Class 1 pathways in
defence against malaria in RTS,S vaccinated subjects. Achieving suf-
ﬁcient power to evaluate global gene expression two weeks after
vaccination in the PBMC of humans who are not acutely unwell
is a challenge because of noise from the heterogeneous genetic
and environmental background of the subjects. Therefore, demon-
stration of differential expression here is a landmark step. The
robustness of this approach is conﬁrmed by a different study by
an independent group [60] which sought to identify a common
“vaccine transcriptomic signature” for responses to ﬁve different
vaccines (two for Neisseria meningitidis, two for inﬂuenza and one
for Yellow Fever). Of 1255 genes identiﬁed as a vaccine transcrip-
tomic signature common to at least 4/5 of the vaccine datasets,
1231 (98%) were present in the dataset from the RTS,S study by
Vahey et al. [59] when the RTS,S study was used as a test dataset.
A smaller study reported in this issue [61] evaluated response
to vaccination in sixteen subjects receiving one of two prime-
boost regimens: either RTS,S/AS02A and MVA-CS (CSP study), or
DNA-ME TRAP and MVA-ME TRAP (TRAP study). 14/16 subjects
underwent sporozoite challenge, and three subjects (two from CSP
study and one from TRAP study) were completely protected against
malaria with others showing a delay to parasitaemia. To focus on
the antigen-speciﬁc response to vaccination, PBMC stimulated with
peptides from the vaccines (either CSP or TRAP) were compared
to paired unstimulated PBMC. To examine the transcription pro-
ﬁle associated with protection against malaria, antigen-stimulated
PBMC were normalised pairwise to matched unstimulated PBMC
prior to analysis. The dominant transcriptional proﬁle seen across
the analyses was upregulation of genes found in the IFN- pathway.
GSEA analysis revealed strong antigen-speciﬁc positive enrich-
ment of genes associated with the proteasome after vaccination
with ME-TRAP, which is consistent with the ﬁndings of Vahey
and colleagues and may  reﬂect the T-cell inducing capabilities of
the prime-boost platform. Antigen-speciﬁc positive enrichment of
genes associated with IFN induction and antigen presentation mod-
ules was seen in subjects with complete protection from malaria
challenge. Antigen-speciﬁc negative enrichment of genes associ-
ated with stem cells, regulatory monocytes and myeloid modules
was seen in protected subjects. This study conﬁrms the beneﬁt of
focussing vaccine development efforts on strategies to optimise
activation of the proteasome for efﬁcient antigen presentation, and
suggests approaches that favour a bias in haemopoietic precursor
development towards lymphoid lineage may  improve efﬁcacy.
5. Limitations, opportunities and the future for
transcriptomics
Transcriptional studies in vaccine research often use small sam-
ple sizes, suffer from limited immunogenicity of the vaccines being
studied and represent a snapshot in time of gene expression. Conﬁr-
mation in new datasets is required, and exploration beyond gene
expression to demonstrate changes at the protein level is desir-
able. Further limits for these studies are the expense and expertise
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involved, but costs are decreasing and training in a systems-
based analytic strategy can “democratize” the bioinformatics [62],
improving accessibility to global multi-lingual researchers. PBMC
are frequently cryopreserved in vaccine studies where cellular
pathways are of interest as a means of sampling the current
immune activity. However the study by Tse et al. [56] is a reminder
of different expression occurring at different sites in the body, and
animal models remain useful for allowing studies of sites inacces-
sible in human trials. The key role of neutrophils in response to
intracellular pathogens is increasingly illuminated by transcrip-
tional studies [63,64] and many researchers prefer to examine
whole blood responses for this reason, although the development
of approaches to examine cell subsets is of great interest [65].
The lack of clearly deﬁned and consistent assays to predict
protective immunity against malaria is a major obstacle in the
development and testing of malaria vaccines. Elucidation of new
correlates of protective immunity may  indicate new targets for vac-
cination and allow efﬁcient monitoring of population’s response to
vaccination. It is also an opportunity to learn more about antigen-
speciﬁc immunity in general. Studies in malaria-naïve populations
using irradiated sporozoites conferring high rates of protection
[14] provide ideal opportunities to compare molecular signatures
before and after immunisation and relate this to challenge, whilst
trials of partially effective vaccines offer the chance to deﬁne
the pattern of difference between protected and non-protected
subjects. Anecdotally a number of researchers in this ﬁeld have
transcriptional proﬁling studies as part of their programme, and we
hope that the next few years will herald more published reports.
Evaluation of response to candidate malaria vaccines in endemic
populations is desirable. There are technical, ﬁnancial and blood
volume-limit difﬁculties in studying transcriptomics in the ﬁeld,
but the establishment of some ﬂexibility in storage conditions for
whole-blood in-tube RNA storage [66], and the development of
solid RNA collection methods for use of dried blood spots [67] offer
potential for tropical settings.
We  live in an exciting time for the deployment of
state-of-the-art tools to reveal the secrets of immunity to complex
pathogens. Future approaches to understanding the mechanisms
of protection of partially effective vaccines such as RTS,S should
include a range of approaches alongside transcriptomics such as
multiplex cytometry, protein arrays [68] and mass spectrometry.
Transcriptomics is broadening our understanding of malaria
vaccine induced protective immunity, and deeper integration
of transcriptomics in clinical malaria vaccine trials will help to
identify immune correlates and guide the design of future malaria
vaccines.
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